WEP Clinical LTD (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available, has partnered with biopharmaceutical company, Solasia Pharma K.K., to launch a Named Patient Program (NPP) for DARVIAS® injection, a treatment for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”).
DARVIAS® is an anti-cancer agent with a novel mechanism of action, which was approved and launched in Japan in 2022 for relapsed or refractory PTCL indication.
The NPP is designed to ensure that physicians in Europe and rest of world territories, where DARVIAS® remains unlicensed, can request DARVIAS® on behalf of individual patients who are in need of a new treatment option in PTCL.
For physicians who are interested in gaining further information on the DARVIAS® Named Patient Program, please contact: darviasnpp@wepclinical.com.
Jas Khera, Managing Director of WEP, said:
“We are excited to partner with Solasia Pharma K.K. to help facilitate broader access to this important therapeutic treatment. Solasia Pharma K.K. has already achieved some important milestones with DARVIAS®, and the WEP Clinical team is looking forward to helping make DARVIAS® available to patients in Europe and rest of the world who have a need for this specific treatment.”
About WEP
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.
About Solasia Pharma K.K.
Solasia Pharma K.K. is a specialty pharmaceutical company, headquartered in Japan and focused on developing and commercializing oncology therapies and supportive care products in Japan, China, and other Asian countries. For more information, please visit www.solasia.co.jp/en/.
